---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-268807"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:25:28.885642+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Seres Q3 2023 VOWST sales $7.6M; cuts 41% workforce, targets $75-85M annual savings

## Summary
- Q3 net loss $47.9M vs $60.0M YoY; VOWST net sales $7.6M from 506 units in first full quarter.
- 1,513 prescription enrollment forms received, 934 patient starts; 698 unique HCPs prescribed VOWST.
- Workforce reduction of ~160 positions (41%) to generate $75-85M annual cash savings in 2024.
- Restructuring focuses on VOWST launch and SER-155 Phase 1b study; cash $169.9M expected into Q4 2024.
- Eligible for $45M Tranche B from Oaktree upon $35M trailing VOWST sales by Sep 2024.

## SEC filing metadata
- accession: 0001193125-23-268807
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312523268807/0001193125-23-268807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312523268807/d559654d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-268807
- JSON: https://secwatch.observer/filing/0001193125-23-268807.json
- Plain text: https://secwatch.observer/filing/0001193125-23-268807.txt

## Key facts
- Earnings Releases
  Seres Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income net loss of $47.9 million.
  - Period: the third quarter ended September 30, 2023
  - Net income: net loss of $47.9 million
  - Result: reported results
  source text: Seres reported a net loss of $47.9 million for the third quarter of 2023, as compared with a net loss of $60.0 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1609809/000119312523268807/0001193125-23-268807-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.